Bristol Myers Squibb Co $50.95

down -0.04


23/4/2014 06:40 PM  |  NYSE : BMY  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get BMY Trend Analysis - it has outperformed the S&P 500 by 1%

Partner Headlines

  1. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  2. UPDATE: Bristol-Myers Squibb Submits NDA to US FDA for Fixed-Dose Combo ...

    Benzinga
  3. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  4. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  5. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  6. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  7. Novo Nordisk Upgraded to 'Buy'

    FoxBusiness
  8. Abbvie Inc. (ABBV) Dividend Stock Analysis

    GuruFocus
  9. Gilead's HCV Challengers Near The Starting Gate

    IBD
  10. Gilead's HCV Challengers Near The Starting Gate

    IBD
  11. Abbott Capturing Incremental Market Share

    GuruFocus
  12. US Stock Futures Jump Ahead Of Economic Data

    Benzinga
  13. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  14. Arrowhead Surges As Analysts Laud Hepatitis B Drug

    IBD
  15. Bristol Moving Ahead With Lung-Cancer Drug Combo

    IBD
  16. Bristol-Myers Squibb's

    IBD
  17. Pfizer Gets Good News For Pneumonia, Bone-Thinner Drugs

    IBD
  18. Market Wrap For February 24: Markets Showing Strength To Start The Week

    Benzinga
  19. FDA Gives Bristol-Myers' Hepatitis Drug 'Breakthrough' Designation

    FoxBusiness
  20. Actavis, Forest In $25 Bil Deal

    IBD
  21. Actavis' Buyout Of Forest Creating Spec Pharma Giant

    IBD
  22. Vanguard Health Care Fund's Top Five

    GuruFocus
  23. UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive ...

    Benzinga
  24. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  25. Investors Brace for Bear Market

    FoxBusiness
  26. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  27. #PreMarket Primer: Monday, January 27: Markets Open The Week On Edge

    Benzinga
  28. Bristol-Myers Int'l Sales Soar

    IBD
  29. Top Earnings-Related Movers for Week of Jan. 20th

    Benzinga
  30. Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

    Benzinga
  31. Bristol Q4 Beats, But Nivolumab Still Worries Market

    IBD
  32. Stocks Open Sharply Lower; Kansas City Southern Collapses

    IBD
  33. Stock Futures Down, Off Lows; Microsoft And Juniper Climb

    IBD
  34. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  35. #PreMarket Primer: Friday, January 24: Growth Fears Drag Down Emerging ...

    Benzinga
  36. Earnings Scheduled For January 24, 2014

    Benzinga
  37. Stocks To Watch For January 24, 2014

    Benzinga
  38. Cancer drug result in question

    IBD
  39. Bristol-Myers' New Nivolumab Trial Sparks Worries

    IBD
  40. Growth Fund Of The Year: Stock Picks

    YCharts
  41. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  42. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  43. Ligand Pharmaceuticals Poised For Full-Year Profit

    IBD
  44. Market Wrap For January 8: Fed Minutes Released

    Benzinga
  45. Daclatasvir Marketing Authorization Application for Treatment of Chronic ...

    Benzinga
  46. The Top Five Drug Launches Of 2013

    IBD
  47. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  48. New Drugs Could Change Cancer Landscape In 2014

    IBD
  49. Benzinga's Top #PreMarket Losers

    Benzinga
  50. 21 Stocks Giving the Gift of Dividend Growth

    GuruFocus
Trading Center